To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Founded in 2017, Heidelberg Delivery Technologies GmbH (HEIDELTEC), offers a novel liposomal matrix system that enables the oral administration of peptide and protein drugs in a solid form, without the need for syringes.
The Heidelberg-based company is a spin-off from the pharmaceutical technology of the Ruprecht-Karls-University of Heidelberg, and is part of the EXIST research transfer program funded by the German Federal Ministry of Economics and Energy.
With its PEPTORAL® technology, HEIDELTEC services clients and licensees from the pharmaceutical industry and the life science sector. By offering them the opportunity to reformulate or newly formulate peptide and protein active ingredients for oral administration. The PEPTORAL® technology uses an innovative, patent-pending, liposomal matrix formulation, which safely encapsulates the active substance during its passage through the stomach, and ensures intestinal absorption into the blood. It offers high storage stability and allows a controlled single dose of the active ingredients.
HEIDELTEC allows the oral administration of peptide and protein-based drugs. Peptide- or protein-based drugs are needed for the treatment of diabetes, cancer and various autoimmune diseases. However, peptides and proteins cannot be administered orally because they are rapidly degraded in the stomach and/or are not absorbed in the intestine and therefore have to be injected. This is the problem that our technology addresses. The PEPTORAL® technology solves the problem of stability in the gastrointestinal tract and increases the uptake of the active ingredients in the intestine, thus providing an oral alternative to injections.